Arizona Sunrise

Essentials of Oncology, Solid Organ and Blood/Marrow Transplant Management for the Health Care Team

Scottsdale, AZ US
April 11, 2019 to April 12, 2019

Exciting, new, relevant topics!

Why should you attend? Whether you are just launching your career in the field of transplantation or oncology or you have been managing transplant or cancer patients for years, this accredited educational activity is designed to deliver the information you need for the care and management of these patient populations.

During this two-day event, you will receive a wide array of valuable information through thought-provoking presentations given by leading medical practitioners from prominent transplant and cancer programs. Faculty will discuss the keys to optimize the management/benefits of individuals with cancer and/or undergoing organ or blood/marrow transplant.

You will hear about advances, trends and updates on relevant topics within these fields, such as medical, psychosocial and surgical transplant management; infectious disease; changes to the national policy on organ allocation; and chimeric antigen receptor (CAR) T-cell therapy. You will learn about the latest guidelines and future applications in transplantation and cancer care, and discover current and emerging strategies to adapt standards and best practices to improve patient care and outcomes.

Commercial support
This activity is supported by educational grants from Sanofi Genzyme and Veloxis Pharmaceuticals, Inc.


Target Audience

Designed for the interprofessional health care team

This educational activity has been developed by the health care team to promote collaborative practice in health care delivery by providing a broad range of topics for a variety of learners. It is intended for health care practitioners that are responsible for the care of transplant and/or oncology patients or management of their benefits, as well as for those who desire to gain or enhance their fundamental knowledge and understanding of transplant medicine and cancer treatments.

Who attends? 
  • Case Managers
  • Managed Care Nurses
  • Medical Directors
  • Nurses/Oncology Nurses
  • Nurse Practitioners
  • Pharmacists
  • Pharmacy Technicians
  • Physicians/PAs
  • Social Workers
  • Transplant Nurses
  • Transplant/Hematopoietic Transplant Coordinators
  • Medical Management Staff
  • Reinsurance Managers
  • Utilization Review Staff

Learning Objectives

After completion of this activity, the participant should be able to:

  • Describe new advances in the treatment of acute myeloid leukemia (AML) and the role of transplantation for multiple myeloma and autoimmune diseases.
  • State the potential impact of normothermic liver preservation on transplant outcomes and waiting list mortality.
  • Recognize the clinical and financial impact of commercially available CAR T-cell therapy.
  • Discuss current research and best-practice standards in pediatric blood/marrow transplant (BMT) and explore transplant barriers to access.
  • List the various types of opportunistic infections in immunocompromised individuals.
  • Explain the various approaches in the medical, psychosocial, and surgical management of heart, lung, kidney, and liver transplantation.
  • Outline recent changes to the adult heart allocation policy and how these changes impact waitlist mortality, outcomes, and provider and patient satisfaction, as well as address the implications for those with ventricular-assist-devices (VADs) as long-term alternatives to transplant.
  • State current and new therapeutic approaches for hepatocellular carcinoma treatment outside of transplant, and describe various bridging treatment techniques to transplant.
  • Address some of the ethical and/or controversial issues surrounding liver transplantation for patients with alcoholic hepatitis.
Activity summary
Available credit: 
  • 12.50 ABTC
  • 12.50 ACPE - Pharmacist
  • 12.50 ACPE - Pharmacy Technician
  • 12.50 AMA
  • 12.50 ANCC
  • 12.50 APA
  • 12.50 Attendance
  • 11.50 CCMC - General
  • 1.00 CCMC - Ethics
  • 12.50 CMCN
  • 12.50 ASWB
Activity opens: 
Activity expires: 
Event starts: 
04/11/2019 - 8:00am EDT
Event ends: 
04/12/2019 - 3:30pm EDT

Don't miss the unique opportunity to reach this targeted audience of health care professionals during “Essentials of Oncology, Solid Organ and Blood/Marrow Transplant Management for the Health Care Team.”

Exhibitor and supporter resources

> Exhibit Space Application
> Support Application
 Exhibitor & Supporter Prospectus
Exhibitor Service Kit (updated 3/28/19)
Floor Plan and Booth Assignments



OptumHealth Education gratefully acknowledges our supporters. Click on the organization's logo to be redirected to its website.

Annual Conference Supporters









Seattle Genetics





Kite Pharma

Event Supporters


Helsinn Therapeutics

Sanofi Genzyme


Event Promotional Supporter

Banner Transplant

The Scott Resort & Spa
4925 North Scottsdale Road
Scottsdale, AZ 85251
United States
+1 (480) 945-7666

The Scott Resort & Spa Information

"Essentials of Oncology, Solid Organ and Blood/Marrow Transplant Management" will be held at The Scott Resort & Spa. Fully renovated and reinvented, The Scott Resort & Spa artfully blends the upscale appeal of a downtown Scottsdale location with the casual elegance of a lush desert retreat. Ideally located in historic Old Town Scottsdale, The Scott is just 12 miles from Phoenix’s Sky Harbor Airport and within walking distance of the Scottsdale Waterfront district with its fabulous boutiques and art galleries, fine dining, cultural attractions, and Scottsdale Fashion Square—the Southwest’s largest shopping destination.

Conference Attire

Suggested attire for the conference is business casual. Although every effort is made to maintain a comfortable learning environment, meeting room temperatures can fluctuate greatly and may be difficult to control. Since it is difficult to adjust meeting room temperatures to suit individual preferences, please bring a sweater or jacket, and/or wear layered clothing to ensure your comfort.


Parking and Ground Transportation

Resort parking and directions: Click here for a local area map.
Complimentary valet and self-parking are included in your resort fee.

Ground transportation: Click here for ground transportation information available at the Phoenix Sky Harbor Airport. Once you arrive at The Scott, complimentary shuttle service is available to locations within a three-mile radius.

> UnitedHealth Group Employee Special Travel Instructions

To Reserve Your Room      Book Now

Each brand new guestroom features a pillow-top mattress, plush feather pillows, luxurious robes, and designer spa-inspired bath amenities.

Hotel reservations:  *** THE ROOM BLOCK IS CURRENTLY SOLD OUT ***
Book your reservation online
Toll-free reservations: (800) 528-7867. To receive the conference discounted room rate, you must reserve your room by Wednesday, March 27 and mention "OptumHealth."

OptumHealth Education appreciates your support in booking your hotel reservation at The Scott Resort & Spa. The number of hotel rooms used for this conference directly impacts hotel rates, conference costs and registration fees. An added benefit to staying at The Scott is the opportunity to continue building relationships with your fellow attendees and exhibitors outside of the educational session hours.

Hotel room rate and fee: $246 per night per room and subject to prevailing state and local taxes. When your reservation is made, The Scott will require a deposit equal to the room rate and tax for the first night of the reservation. The deposit is refundable if The Scott receives your cancellation notice at least 72 hours prior to your scheduled arrival date.

A daily resort fee of $10, plus applicable occupancy and sales taxes, will be charged per room per night (discounted from $37). This fee includes the following: self- and valet-parking, round-trip porterage, daily maid gratuity, resort shuttle providing transportation within three miles, wi-fi in guest rooms and public space, in-room Nespresso, 24-hour access to fitness center and business center, and daily newspapers upon request.

Reservation deadline: Wednesday, March 27, 2019, or when rooms sell out, whichever comes first. Reservations made after this date, or after the room block is sold out, will be accepted on a space-available basis at the prevailing room rate. Scottsdale is a popular destination, so reserve your room early!

Attention UnitedHealth Group, UnitedHealthcare, Optum Employees

To book your hotel stay: To reserve a room at The Scott Resort & Spa, please follow the reservation instructions listed above to receive the group discounted rate (do not use Concur or BCD Travel for The Scott reservations).

To book your flight: Due to a recent procedure change, employees traveling for this conference are exempt from the pre-trip approval process. The Travel Request form is NOT required. To qualify, employees MUST book airline reservations directly with BCD Travel and reference Group #UHG1036948. If you book through Concur, you will NOT receive the exemption. You will receive a declined message to cancel your reservation and you must then have an approved Travel Request prior to booking.

  1. DO NOT BOOK through Concur
  2. Call BCD Travel Desk at 1-800-238-9047
    • BCD Travel Business Hours are Monday–Friday 7 a.m.–6 p.m. central time
  3. Reference Group # UHG1036948
  4. After receiving your confirmation, verify that your name matches your valid ID.
  5. Double check dates, time and that airport information is correct. If changes need to be made, call the BCD Group Air Desk directly at 1-800-238-9047.
  6. Book air by March 26, 2019.

Faculty and Planning Committee

Click here for a list of faculty and planning committee members.


Printable Schedule-at-a-Glance (Updated: 03/05/2019)

Thursday, April 11
Friday, April 12

THURSDAY, APRIL 11, 2019Up to 6.75 continuing education credits available. — ACPE UAN JA0007123-0000-19-006-L01-P/T

7:00 a.m.

Registration and Continental Breakfast

8:00 a.m.

Welcome and Opening Remarks

8:15 a.m.

Normothermic Liver Preservation: Current Status and Future Directions, R. Mark Ghobrial, MD, PhD, FACS, FRCS, Houston Methodist

Liver transplantation is severely limited by the shortage of donor organs and, in addition, many potential donor organs cannot be used because suboptimal livers do not tolerate conventional cold storage. Normothermic machine perfusion (NMP) is an emerging technology that has the potential to transform liver preservation and the field of transplantation. This presentation will discuss the role of NMP as a tool to assess graft viability and its potential impact on liver transplant waiting list mortality.

Learning objectives:

  1. Explain the process of NMP.
  2. State the current status of NMP and its potential impact on liver transplant outcomes and waiting list mortality.

9:15 a.m.

Lung-in-a-Box: Advances in Lung Transplant Technology, Michael A. Smith, MD, Norton Thoracic Institute, St. Joseph’s Hospital and Medical Center

For individuals with severe lung disease, a lung transplant is an effective treatment. New advances in lung transplant technology have extended the life of a lung once it has been removed from the donor’s body. This session will discuss the advances in lung transplant technology that aim to increase the supply of donor lungs and maximize transplant outcomes.

Learning objectives:

  1. Describe lung-in-a-box technology.
  2. Discuss the advantages of using lung-in-a-box.
  3. Explain the effect of lung-in-a-box on long-term outcomes.

10:00 a.m.


10:15 a.m.

Jerry Estep, MD, Cleveland Clinic


Innovations in Left Ventricular Assist Devices (LVADs) for End-stage Heart Failure

The number of individuals with end-stage heart failure continues to increase, but there has been little change in the availability of organs for cardiac transplantation. Therefore, the demand for LVADs as a bridge to transplantation, destination therapy or bridge to recovery has increased. This session will discuss how LVAD technology has evolved, resulting in improvements in outcomes. It will also review the importance of appropriate patient selection and implementation of a multidisciplinary team approach as keys to improved clinical outcomes.

Learning objectives:

  1. Review recent changes in technology, patient selection, management and implant decision making in LVAD therapy.
  2. State the importance of a multidisciplinary team approach in the management of LVAD patients to improve morbidity and mortality.


New Allocation Policy for Heart Transplant

In October 2018, the United Network for Organ Sharing (UNOS) implemented extensive changes to its adult-heart-allocation policy. The modifications are aimed at better stratifying the most medically urgent heart transplant candidates and addressing geographic disparities that impact access to donor organs. It also takes into account the increasing effectiveness and growing use of mechanical circulatory support devices (MCSDs) used to treat heart disease. This session will describe the principles guiding geographic organ distribution, including the paradigm shift for individuals with MCSDs.

Learning objectives:

  1. Describe the principles guiding geographic organ distribution.
  2. Discuss the paradigm shift for individuals with MCSDs awaiting heart transplantation.
  3. Outline changes designed to decrease mortality rates for heart transplant-eligible patients on the waitlist.

11:15 a.m.

New Allocation Systems and Policy Changes for Liver Transplantation, Shivang Mehta, MD, Banner University Medical Center

Allocation of liver donor organs in the United States is a complex and evolving process. New allocation/distribution systems are in development that attempt to more accurately allocate organs. This session will address the major paradigm shifts that are underway to improve the equitable allocation of livers for individuals waiting for a liver transplant. Policy changes addressing geographic disparities without compromising outcomes will also be discussed.

Learning objectives:

  1. State ongoing challenges and limitations to the current organ allocation and distribution policy for liver transplants.
  2. Review major policy changes in liver allocation, including those addressing geographic disparities.

12:00 p.m.

Luncheon Presentation — An Overview of Optum® (nonaccredited/optional; lunch provided)

1:00 p.m.

Exhibit Hall Grand Opening Dessert Reception

1:30 p.m.

Increasing Kidneys for Transplantation: Decreasing Discards, Matthew Cooper, MD, Medstar Georgetown Transplant Institute

Approximately 12 people die each day waiting for a kidney transplant while about 10 kidneys are discarded daily. A recent report that focused on decreasing the number of discarded kidneys provides the first systematic nationwide approach to reducing kidney discards. The “Report of National Kidney Foundation Consensus Conference to Decrease Kidney Discards” is the result of a year-long effort with leading transplantation experts in the United States devoted to solving the kidney utilization problem. This presentation will review the findings of the report and identify its recommendations to increasing the utilization of procured kidneys and providing opportunities for transplantation that are currently falling short of the demand.

Learning objectives:

  1. Explain why so many kidneys are discarded.
  2. Identify the recommendations published in the “Report of National Kidney Foundation Consensus Conference to Decrease Kidney Discards.”
  3. State ways in which the utilization of procured kidneys could be increased to provide opportunities for transplantation.

2:15 p.m.

Liver Transplantation for Patients with Alcoholic Hepatitis, Michael Abecassis, MD, MBA, Northwestern Memorial Hospital

With advances in the prevention and therapy of viral hepatitis, the percentage of patients with alcohol-associated liver disease requiring liver transplantation is increasing with a growing recognition of liver transplantation as a rescue therapy for individuals with severe alcoholic hepatitis (AH) not responding to medical therapy. Treatment guidelines adopted by most liver transplantation centers require a six-month period of alcohol abstinence and counseling prior to candidacy for liver replacement. In many cases individuals with severe AH do not have the luxury of waiting and are unlikely to survive six months. This session will review liver transplantation for alcoholic liver disease, discuss the selection process to evaluate eligibility on a case-by-case basis, address specific factors that should be considered during evaluation, and explore whether a mandatory period of abstinence is a predictor of relapse and the ethical considerations surrounding such a requirement for patients’ transplant eligibility.

Learning objectives:

  1. Review liver transplantation for alcoholic liver disease, including the selection process for transplant eligibility.
  2. Identify specific factors that should be addressed when evaluating individuals for liver transplant.
  3. Discuss whether a mandatory period of alcohol abstinence is a predictor of relapse.
  4. Explore ethical considerations on the eligibility of liver transplant candidates.

3:15 p.m.


3:30 p.m.

Psychosocial Evaluation of Adult Cardiothoracic Transplant Candidates and Candidates for Long-term Mechanical Circulatory Support, Kathleen L. Grady, PhD, RN, MS, FAAN, Northwestern Memorial Hospital

The psychosocial evaluation is well-recognized as an important component of the multifaceted assessment process to determine candidacy for cardiothoracic transplantation and long-term mechanical circulatory support. Due to the lack of a consensus-based set of recommendations for psychosocial assessment during the evaluation, a committee composed of international experts representing the International Society for Heart and Lung Transplantation (ISHLT) and collaborating societies was formed. This committee integrated expert opinion and conducted a comprehensive literature review to support the psychosocial evaluation content and process recommendations. These recommendations are designed to promote consistency across programs in the performance of the psychosocial evaluation. This session will review the recommendations for a psychosocial evaluation and identify factors that could impede recovery, compliance, and a successful postoperative period.

Learning objectives:

  1. Describe the content and process recommendations for a psychosocial evaluation to determine candidacy for cardiothoracic transplantation and long-term mechanical circulatory support.
  2. Identify factors that could impede recovery, compliance and a successful postoperative period.

4:15 p.m.

Hepatocellular Carcinoma: Treatment Options Outside of Transplant, Christopher J. Sonnenday, MD, MHS, Michigan Medicine

Liver transplantation (LT) is considered the best curative treatment for patients with cirrhosis and hepatocellular carcinoma (HCC) within Milan criteria. Several therapeutic procedures have been proposed as bridging treatments for individuals with HCC awaiting LT. The choice of each treatment is based on: the characteristics of the patient; liver function; comorbidities; and on the number, dimensions, and localization of HCC. This session will describe the various bridging techniques for individuals with HCC awaiting LT and the impact of bridging treatments on the recurrence of HCC and survival after LT, as well as treatment options for individuals when transplant is not an option.

Learning objectives:

  1. Describe the various bridging techniques for individuals with HCC awaiting LT.
  2. Discuss the impact of bridging treatments on the recurrence of HCC and survival after LT.
  3. Identify treatment options for HCC when transplant is not an option.

5:00–6:30 p.m.

Complimentary Get-Acquainted Reception — Exhibits Open
Join your colleagues for hors d’oeuvres and beverages. You won’t want to miss this opportunity to gather information and ideas from exhibitors regarding the management of complex medical conditions.

FRIDAY, APRIL 12, 2019Up to 5.75 continuing education credits available. — ACPE UAN JA0007123-0000-19-006-L01-P/T

7:00 a.m.

Registration and Continental Breakfast — Exhibits Open

8:00 a.m.

Opening Remarks

8:15 a.m.

CAR T-cell Therapy: A Personalized Immunotherapy Approach to Cancer, Shannon L. Maude, MD, PhD, Children's Hospital of Philadelphia

While chimeric antigen receptor (CAR) T-cell therapy has proven successful in treating certain cancers, severe toxicities have limited its widespread application. This new cancer treatment approach is powerful and does come with serious risks that need to be considered before starting therapy. This session will identify the indications for CAR T-cell therapy and describe the challenges from the toxicities that are unique to CAR T cells. Toxicity management will also be discussed.

Learning objectives:

  1. Describe CAR T-cell therapy.
  2. Identify the indications for CAR T-cell therapy and individuals that are appropriate candidates.
  3. Discuss the challenges of toxicities that are unique to CAR T cells.

9:15 a.m.

Non-HLA Barriers to Blood/Marrow Transplant, Nandita Khera, MD, MPH, Mayo Clinic

Historically, the lack of finding a human leukocyte antigens (HLA)-match has been perceived as the largest barrier to BMT. Many barriers besides a lack of suitably matched donors exist and can have an adverse impact on access and outcomes of BMT. This session will identify key barriers to BMT including barriers that prevent access to care, such as language and cultural differences; illiteracy; and environmental, geographic, genetic, and medical barriers. Ethical dilemmas that confront patients, families and medical practitioners will also be discussed.

Learning objectives:

  1. List key barriers to BMT.
  2. Discuss the inequalities and disparities in access to transplantation and solutions that may be applied to minimize these.
  3. Identify ethical dilemmas to transplantation that patients, families and medical practitioners encounter.

10:00 a.m.

Break — Exhibits Open

10:45 a.m.

Pediatric Blood/Marrow Transplant Overview, Reggie E. Duerst, MD, Ann & Robert H. Lurie Children's Hospital of Chicago

A blood/marrow transplant (BMT) is a treatment for children with certain types of cancer or other diseases. The goal of BMT is to treat or cure disease, which can include various types of pediatric cancers, disorders of the blood and immune system, and a wide variety of other rare disorders and syndromes. This session will highlight the different sources for blood/marrow transplants and discuss the indications, risks, benefits, and outcomes.

Learning objectives:

  1. Describe the different sources for blood/marrow transplant used to treat or cure disease.
  2. List the the wide variety of pediatric cancers, disorders and syndromes that are treated with a BMT.
  3. Discuss the indications, risks, benefits and outcomes of BMT.

11:45 a.m.

Acute Myelogenous Leukemia (AML): New Therapies after 40 Years! Fiona C. He, MD, University of Minnesota

AML is one of the most aggressive cancers. While other cancers have benefited from new treatments, there has been no encouraging news for most leukemia patients for the past 40 years. With improved biologic understanding of AML and the incorporation of genetic prognostic markers and novel therapeutic options bringing new advancements to the field, individuals with AML have reason to hope. This session will review recent advances and new agents that have been approved for the treatment of AML and discuss the role of biomarkers in AML treatment decisions.

Learning objectives:

  1. Review recent advances for the treatment of acute myelogenous leukemia.
  2. Discuss four new agents that have been approved for the treatment of AML.
  3. Describe the role of biomarkers in AML treatment decisions.

12:30 p.m.

Lunch (provided)

1:15 p.m.

Multiple Myeloma: What’s New in Treatment Options, Jonathan L. Kaufman, MD, Winship Cancer Institute of Emory University

Over the past decade, treatment options for multiple myeloma have increased substantially. New treatments have resulted in improved survival rates among individuals with multiple myeloma. A BMT, in combination with high-dose chemotherapy, is a treatment option that offers a chance for durable remission for individuals with multiple myeloma. Treatment goals can vary significantly from person to person and can have a substantial impact on the type(s) and duration of treatment individuals receive. This session will outline the diagnostic criteria and review the revised international staging system for myeloma. Current concepts in cytogenetic classification, risk stratification and therapy will also be discussed.

Learning objectives:

  1. State current concepts in cytogenetic classification and therapy for myeloma.
  2. Discuss risk stratification of myeloma.
  3. Review the revised international staging system for myeloma.

2:00 p.m.

Blood/Marrow Transplant for Autoimmune Disease, Matthew Mei, MD, City of Hope

Autoimmune diseases are caused by an overactive immune system that targets the patient’s own cells. Most individuals with autoimmune disorders respond to conventional drug therapies; however, conventional drug therapies are not curative. Although not all autoimmune diseases can be treated with a BMT, the primary concept underlying use of a BMT for these diseases is that ablating and “resetting” the immune system can alter the disease process. This session will discuss the autoimmune diseases that are treated with a BMT, the impact on a patient’s quality of life, treatment-related mortality and morbidity, and overall survival after BMT.

Learning objectives:

  1. Identify diseases that can be treated with a BMT.
  2. Describe the primary concept underlying use of a BMT for treatment of autoimmune disease.
  3. State treatment-related mortality and morbidity, as well as the impact on quality of life for BMT recipients with autoimmune disease.

2:45 p.m.

Opportunistic Infections in the Immunocompromised, Jeffery J. Auletta, MD, Nationwide Children's Hospital

Opportunistic infections are infections that occur more often or are more severe in individuals with weakened immune systems than in people with healthy immune systems. Immunocompromised individuals are at high risk for developing opportunistic infections that can potentially be fatal. This session will discuss causes for immunosuppression and the variety of opportunistic infections—including bacterial, viral and fungal—that immunocompromised individuals can develop.

Learning objectives:

  1. Discuss causes for immunosuppression.
  2. Provide examples of some of the most common opportunistic bacterial, viral and fungal infections.

3:30 p.m.



Note: OptumHealth Education reserves the right to make any necessary changes to this program. Efforts will be made to keep presentations as scheduled. However, unforeseen circumstances may result in the substitution of faculty or content.
Last updated: 03/05/19

Maximum CE Credits Available:  12.50
Thursday, April 11 — Up to 6.75 CE Credits
Friday, April 12 — Up to 5.75 CE Credits

Accreditation Statement

Joint Logo

In support of improving patient care, OptumHealth Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.

Credit Designation Statements


This activity was planned by and for the health care team, and learners will receive 12.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

OptumHealth Education designates this live activity for a maximum of 12.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Academy of PAs (AAPA) accepts credit from organizations accredited by the ACCME.

AAPC-Certified Coders
AAPC will honor 1-for-1 CEUs for any live event offering CME credit or AMA PRA Category 1 Credit. A certificate of attendance or completion is necessary to show participation. The certificate will give the total CMEs possible for the offering. Physicians are advised to claim only the actual hours that they were present during the education. We ask that AAPC-certified members abide by this request also. One hour of instruction is worth one CEU.

Pharmacists/Pharmacy Technicians
This activity is approved for 12.5 contact hours (1.25 CEUs) in states that recognize ACPE.
Attending the full program will earn 12.5 contact hours (1.25 CEUs).
Unique Activity Number JA0007123-0000-19-006-L01-P/T

The participant will be awarded up to 12.50 contact hours of credit for attendance and completion of supplemental materials.

Nurse Practitioners
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts credit from organizations accredited by the ACCME and ANCC.

Case Managers


This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 11.5 CE contact hours.
Activity code: C00036600 Approval Number: 190001115

This program has been pre-approved by The Commission for Case Manager Certification to provide Ethics continuing education credit to CCM® board certified case managers. The course is approved for 1.0 CE contact hours.
Activity code: C00036583 Approval Number: 190001112

CCMC Ethics credit is approved for this course. The CCMC Code of Professional Conduct will be referenced in this presentation. View the CCMC Code of Professional Conduct here.

To claim these CEs, log into your CE Center account at

Managed Care Nurses
This activity has been approved for a maximum of 12.5 clock hours for Certified Managed Care Nurse (CMCN) recertification by the American Board of Managed Care Nursing (ABMCN).

Medical Assistants
The American Association of Medical Assistants allows up to 30 non-AAMA recertification points for CMAs (AAMA) who are recertifying by continuing education. Please see the following link for more information:

OptumHealth Education is approved by the American Psychological Association (APA) to offer continuing education for psychologists. OptumHealth Education maintains responsibility for this program. 12.50 CE hour.

Social Workers

ACE Logo

As a Jointly Accredited Organization, OptumHealth Education is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. OptumHealth Education maintains responsibility for this course. Social workers completing this course receive up to 12.50 live continuing education credits.

Transplant Coordinators, Transplant Nurses, Procurement Transplant Coordinators
The American Board for Transplant Certification (ABTC) has approved this educational offering for up to 12.5 Category 1 Continuing Education Points for Transplant Certification (CEPTCs).

Hematopoietic Transplant Coordinators
This learning activity qualifies towards recertification for certified hematopoietic transplant coordinators (CHTC).

ILNA Coding
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
List of available ILNA points: >by Session; >by Subject Area. Total ILNA points available: 6.5

Disability Access: If you require ADA accommodations please contact our office 10 days or more before the event. We cannot ensure accommodations without adequate prior notification.

Please Note: Licensing Boards change regulations often and while we attempt to stay abreast of their most recent changes, if you have questions or concerns about this course meeting your specific board’s approval, we recommend you contact your board directly to obtain a ruling.

A certificate of attendance will be provided to learners upon completion of activity requirements, enabling participants to register with licensing boards or associations that have not been preapproved for credits. To apply for credit types not listed above, participants should use the procedure established by the specific organization from which they wish to obtain credit.

Conference Evaluation and Certificate of Attendance Request Process

A Certificate of Attendance will be available at the conclusion of the conference. Check back at that time for instructions regarding the Certificate of Attendance Request and Conference Evaluation process.

Available Credit

  • 12.50 ABTC
  • 12.50 ACPE - Pharmacist
  • 12.50 ACPE - Pharmacy Technician
  • 12.50 AMA
  • 12.50 ANCC
  • 12.50 APA
  • 12.50 Attendance
  • 11.50 CCMC - General
  • 1.00 CCMC - Ethics
  • 12.50 CMCN
  • 12.50 ASWB


Please login to register.
Early Bird Registration Deadline: March 20, 2019. The $50 discounted rate expires after this date.
Single-Day Attendance: If you live in the Scottsdale/Phoenix area and can only attend for one day, take advantage of our 35% discounted rate—a CE bargain. Use coupon code OneDay35 during check out.

Registration Information

Registration includes: Conference sessions, program syllabus, continuing education record-keeping and certificate of attendance, continental breakfasts, breaks, lunches, and networking reception.

Registration confirmation: Upon successful completion of registration, a confirmation will be sent to the email address in the registrant's profile. If you do not receive a confirmation email within 10 minutes, please request assistance at

Cancellation policy:  Send cancellation requests to A $25 processing fee will be assessed on cancellations received by March 20, 2019. Only medically verifiable cancellations will be considered for partial refund after March 20, 2019.

Right of refusal: OptumHealth Education reserves the right to refuse conference registration and attendance.

Consent to use photographic and video images: Registration and attendance at or participation in OptumHealth Education activities constitutes an agreement by the registrant to OptumHealth Education’s use and distribution (both now and in the future) of the registrant or attendee’s image.

Questions: Email